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hematology(n= 62), dermatology(n= 14) and psychiatry(n= 72), others(n= 3) from 
outpatient and inpatient care. The survey consisted of qualitative and quantita-
tive questions covering areas such as the most trusted sources of RWE in Poland, 
pharma role in RWE generation vs. government’s contribution, most desired type 
of RWE. The questionnaires were collected Sept-Nov 2014 (the total number of 
responses received n= 251). Data were analyzed using simple descriptive statis-
tics. Results: Physicians demonstrated high degree of interest in evidence on 
practical outcomes, particularly in data on safety and effectiveness of treatment 
(over 90% of responders); at the same time 1 out of 5 doctors claimed that data 
on effectiveness are hardly accessible in Poland. Interesting differences regarding 
desired real life data were observed across specialties: i.e. treatment pathways and 
prescribing patterns were frequently valued by diabetologists (87%), while quality 
of life was often quoted by hematologists (87%). For psychiatrists (69%) data on 
direct treatment costs are highly important whereas data on patient compliance 
was most often mentioned by oncologists (79%). ConClusions: The research 
showed high physicians’ interest in practical evidence and the variety of RWE 
perception. The differences in priorities between specializations indicate unmet 
needs in therapeutic areas. Broadening doctor’s and other stakeholders knowledge 
in RWE data significance and improving its accessibility could be crucial for gain-
ing doctor’s advocacy for shaping RWE landscape in Poland and, consequently, for 
improving patient’s treatment results.
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objeCtives: There is limited evidence of the association between spatial segre-
gation by income and health outcomes worldwide. Our objective was to deter-
mine crude and adjusted associations between self-reported disability and four 
measures of spatial segregation by income at individual, household, borough, and 
health service level in Chile. Methods: Secondary analysis of representative, 
anonymous CASEN 2009 survey (n= 105,508 of > 20 years age participants from 
45,021 households/ 315 boroughs/ 29 health services). The relationship between 
self-reported disability (physical, sensorial, psychiatric/cognitive) and spatial 
segregation by income (isolation index, dissimilarity index, Jargowsky coeffi-
cient) was explored using 4-level multilevel logistic regression. Control variables 
were health service´s income inequality (GINI coefficient), age, sex, equivalized 
household income and educational level. The analysis was stratified by house-
hold material poverty (as defined in 2009; around USD$130 per month). Results: 
Individuals living below the poverty line showed a positive association between 
spatial isolation and overall and sensorial self-reported disability. However, there 
was a protective association between spatial isolation and psychiatric/cognitive 
self-reported disability. Otherwise, people living above the poverty line, showed 
a positive association between spatial isolation and overall, physical, sensorial 
and indeed psychiatric/cognitive self-reported disability. Dissimilarity index and 
Jargowsky coefficient did not show any significant association. Besides, equival-
ized household income, education, sex and age were important factors associ-
ated with self-reported disability, but not for income inequality. ConClusions: 
Some measures of spatial segregation (isolation) were associated with self-
reported disability, even after adjusting for health service´s income inequality 
and individual-level socio-demographics. These associations may differ depend-
ing on the presence of absolute poverty and, hence, further research is urgently 
required.
PHP160
multIPle cHronIc condItIons and bmI: PoPulatIon estImates for 
HealtH decIsIon makIng In Puerto rIco
Amill A.1, Serrano R.1, González E.2, Pérez-Perdomo R.3
1Puerto Rico Department of Health, San Juan, PR, USA, 2Johns Hopkins, Baltimore, MD, USA, 
3Centro de Diabetes para Puerto Rico, San Juan, PR, USA
objeCtives: Multiple chronic conditions (MCCs) are related to increased health 
care services and cost and decreased quality of life. Due to the broad implications 
of MCCs and Body Mass Index (BMI) for Health Policy, this study evaluated the 
relation between MCCs and BMI through population estimates, accounting for 
demographic characteristics and risk factors. Methods: Data from the cross-
sectional telephone survey Behavioral Risk Factor Surveillance System, for years 
2011 and 2013 (N= 12,624), was used to obtain the self-reported count of chronic 
conditions (CCs) and BMI. This study included adults 18 years or older living in 
Puerto Rico with 1 to 6 diagnoses of CCs, and with BMI (kg/m^2) between 20.0 and 
45.99. Females that reported pregnancy at time of survey were excluded from 
analysis. Survey-weighted summary statistics were estimated and Poisson regres-
sion coefficients and standard errors (S.E.) calculated using generalized linear 
models in R. Results: The study population (n= 7,830) represented approximately 
1,462,598 adults (55.9%, 95% confidence interval [C.I].: 54.7-57.0). The estimated 
MCCs prevalence was 56.1% (95% C.I.: 54.7-57.0), whereas the BMI mean was 28.7 
kg/m^2 (S.E= 0.08). After adjusting by age, gender, income, smoking status, binge 
drinking, and high cholesterol the regression model showed that the possibil-
ity of reporting more than one chronic condition increases 2.0% (S.E. = 0.16%) 
with an increment in a BMI unit. The most prevalent combinations of two and 
three chronic conditions were arthritis-hypertension (10.7%, 95% C.I.: 9.7-11.7), 
and diabetes-arthritis-hypertension (5.4%, 95% C.I.: 4.7-6.1). ConClusions: 
Study results suggested that in adults living in Puerto Rico with a chronic con-
dition, the possibility of reporting an additional chronic condition increases as 
BMI increases. Decision makers should use these findings to support popula-
tion interventions for weight reduction, policy evaluation, and development of 
MCC guidelines in an effort to improve quality of life and decrease health care 
spending.
and 9 “No Improvement” by the TC. For 22 “No Benefit” judged by the GBA, 21 
were determined “No Improvement” and 1 “Do Not Recommend” by the TC. Of the 
26 anti-cancer indications evaluated, similar patterns were observed. Regarding 
comparators, the TC tended to list multiple whereas the GBA usually used one. 
In 12 assessments (18%), a completely different comparator was used by the two 
agencies. ConClusions: While German and French HTA agencies had similar 
HTA evaluations for a majority of assessments, some differences were noted. 
Notably, the TC tended to be more restrictive and apply multiple comparators in 
its HTA evaluations.
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objeCtives: The Scottish Medicines Consortium (SMC) requires all manufactures 
to submit clinical and economic evidence for products no later than 3 months 
after licensing. Any products without a submission are automatically not rec-
ommended. Due to the complexity of the UK market access environment, small 
or medium pharmaceutical enterprises (SMEs) may not have the knowledge or 
resource to generate submissions for all products. In 2015, the SMC aim to improve 
early engagement with SMEs. To establish the importance of this engagement, 
we assess the differences in submissions and recommendations between SMEs 
and larger companies. Methods: Categorizing the top 30 pharmaceutical com-
panies (based on gross revenue) of 2013 as large companies and all other sub-
mitting companies as SMEs, SMC recommendations following full, abbreviated 
or resubmissions were analyzed along with the proportion of non-submissions. 
Recommendations for co-marketed products were divided evenly between manu-
facturers. Results: There is a statistically significant relationship between the 
proportion of positive guidance for large companies and SMEs (75.47% versus 
64.62%, p= 0.0002). The number of non-submissions from large companies was 
14 in 2012, 18 in 2013 and 8 in 2014; from SMEs the number of non-submissions 
was 11 in 2012, 7 in 2013 and 6 in 2014. ConClusions: There is a relationship 
between company size, based on revenue, and likelihood of a positive SMC recom-
mendation, but identification of the cause and effect requires further analysis. 
These results could indicate that large pharmaceutical companies have a greater 
influence on the decisions of the SMC, or simply more experience and resource 
to increase the chances of success. In 2014, the 30 largest companies accounted 
for more non-submissions than all other pharmaceutical companies, suggesting 
that large companies can afford to pick and choose whether to submit to the SMC 
or gain reimbursement through alternative channels whilst avoiding the wider 
impact of negative guidance.
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objeCtives: Medical Apps nowadays play a pivotal role in managing individuals 
in health and wellness Management and subsequently also useful to the health-
care professionals. The existing studies or results emphasize only on benefits of 
smartphones or usage of medical apps. Present study aims to evaluate the medi-
cal apps and the promotional strategies adopted by the developers to enhance 
app downloads and ratings. Methods: 150 medical and healthcare Android 
Apps were randomly selected from India and other countries including USA, UK, 
Australia. These apps were evaluated with regard to number of downloads, critical 
reviews by the user, rater’s rating, rating by the users and app content by using the 
data collection form. The promotional strategies adopted by these app developers 
were also studied. SPSS 15.0 was used to statistically analyze the data. Chi square 
test was applied to assess association between the number of downloads and 
various promotional strategies adopted (P< 0.05). Mann-Whitney test was used 
to find the promotional strategies resulting in to Five Star ratings. Results: 
The study revealed that there are no stringent regulations and guidelines with 
respect to medical apps in India. Whereas various parameters were extensively 
used in countries such as USA, Australia and EU like usage of HD images, sugges-
tive/awareness, specificity of the disease which aren’t so regular with respect to 
Indian app developers. There was a significant association between downloads 
and promotional strategies such as google search, websites, social media, review 
ratings. ConClusions: This study clearly suggests the promotional strategies 
which can be adopted by the existing and new app developers to have high down-
load success rates. Hence study is highly useful to start ups and existing small 
entrepreneurs.
HealtH care use & PolIcy studIes – Patient registries & Post-marketing 
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objeCtives: Real World Evidence (RWE) is likely to become increasingly impor-
tant in decisions that affect patient’s access to medicines worldwide. However, 
absence of long-term patient registries and electronic documentation consti-
tute the greatest barriers for generating RWE studies in Poland. Therefore, an 
exploratory survey was undertaken to map current awareness and expectations 
of physicians related to practical outcomes data and to identify pharmaceuti-
cal industry’s role in RWE generation. Methods: The study was conducted 
across 6 doctors’ specialties: diabetology(n= 30), virology(n= 42), oncology(n= 28), 
